“FLOW Trial: Semaglutide and 24% Fewer Kidney Events The first dedicated GLP-1 kidney-outcomes trial in type 2 diabetes and CKD”, d, vol. 4, no. 20, pp. 40–41, Jul. 2026, Accessed: Jul. 28, 2026. [Online]. Available: https://thediabzen.com/index.php/d/article/view/63